279 related articles for article (PubMed ID: 16733480)
1. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.
Geier DA; Geier MR
Med Sci Monit; 2006 Jun; 12(6):CR231-9. PubMed ID: 16733480
[TBL] [Abstract][Full Text] [Related]
2. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
Geier D; Geier MR
Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
[TBL] [Abstract][Full Text] [Related]
3. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.
Geier DA; Geier MR
Med Sci Monit; 2005 Apr; 11(4):CR160-70. PubMed ID: 15795695
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.
Geier DA; Geier MR
J Toxicol Environ Health A; 2006 Aug; 69(15):1481-95. PubMed ID: 16766480
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States.
Geier DA; Geier MR
Neuro Endocrinol Lett; 2006 Aug; 27(4):401-13. PubMed ID: 16807526
[TBL] [Abstract][Full Text] [Related]
6. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.
Young HA; Geier DA; Geier MR
J Neurol Sci; 2008 Aug; 271(1-2):110-8. PubMed ID: 18482737
[TBL] [Abstract][Full Text] [Related]
7. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.
Geier DA; Geier MR
Pediatr Rehabil; 2003; 6(2):97-102. PubMed ID: 14534046
[TBL] [Abstract][Full Text] [Related]
8. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.
Geier DA; Geier MR
Med Sci Monit; 2004 Mar; 10(3):PI33-9. PubMed ID: 14976450
[TBL] [Abstract][Full Text] [Related]
9. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
[TBL] [Abstract][Full Text] [Related]
10. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.
Geier DA; Mumper E; Gladfelter B; Coleman L; Geier MR
Neuro Endocrinol Lett; 2008 Apr; 29(2):272-80. PubMed ID: 18404135
[TBL] [Abstract][Full Text] [Related]
11. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.
Parker SK; Schwartz B; Todd J; Pickering LK
Pediatrics; 2004 Sep; 114(3):793-804. PubMed ID: 15342856
[TBL] [Abstract][Full Text] [Related]
12. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.
McMahon AW; Iskander JK; Haber P; Braun MM; Ball R
Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701
[TBL] [Abstract][Full Text] [Related]
13. Continuing increases in autism reported to California's developmental services system: mercury in retrograde.
Schechter R; Grether JK
Arch Gen Psychiatry; 2008 Jan; 65(1):19-24. PubMed ID: 18180424
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adverse event reporting system reporting source: a possible source of bias in longitudinal studies.
Goodman MJ; Nordin J
Pediatrics; 2006 Feb; 117(2):387-90. PubMed ID: 16452357
[TBL] [Abstract][Full Text] [Related]
15. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice.
Berman RF; Pessah IN; Mouton PR; Mav D; Harry J
Toxicol Sci; 2008 Feb; 101(2):294-309. PubMed ID: 17977901
[TBL] [Abstract][Full Text] [Related]
16. [Mercury in vaccines].
Hessel L
Bull Acad Natl Med; 2003; 187(8):1501-10. PubMed ID: 15146581
[TBL] [Abstract][Full Text] [Related]
17. The risk of neurodevelopmental disorders following Thimerosal-containing Hib vaccine in comparison to Thimerosal-free Hib vaccine administered from 1995 to 1999 in the United States.
Geier DA; Kern JK; Homme KG; Geier MR
Int J Hyg Environ Health; 2018 May; 221(4):677-683. PubMed ID: 29573974
[TBL] [Abstract][Full Text] [Related]
18. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.
Geier MR; Geier DA
Exp Biol Med (Maywood); 2003 Jun; 228(6):660-4. PubMed ID: 12773696
[TBL] [Abstract][Full Text] [Related]
19. Update on the National Vaccine Injury Compensation Program.
Edlich RF; Olson DM; Olson BM; Greene JA; Gubler KD; Winters KL; Kelley AR; Britt LD; Long WB
J Emerg Med; 2007 Aug; 33(2):199-211. PubMed ID: 17692778
[TBL] [Abstract][Full Text] [Related]
20. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
Chang S; Ball R; Braun MM
Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
